Screening for prostate cancer now possible – Stockholm3 wins European Innovators Award

Published 2017-10-18 15:59. Updated 2017-10-19 15:45Denna sida på svenska

Stockholm3, the new and innovative prostate cancer test based on research in Henrik Grönberg’s group at Karolinska Institutet, has been rewarded with the EIT Innovators Award. EIT Innovators Award recognizes products and services with a very high potential for societal and economic impact.

Martin Steinberg från STHLM3-projektetStockholm3 is a blood test that detects the risk of aggressive prostate cancer by combining five protein markers, more than 100 genetic markers, clinical data and a proprietary algorithm. Stockholm3 finds 20% more aggressive cancers and at the same time reduces the number of unnecessary treatment by 50%. If screening for prostate cancer based on Stockholm is introduced in Europe it is possible to save 500,000 men from unnecessary and dangerous treatments and save millions for society. The Swedish National Board of Health and Welfare is expected to reach a decision about a Swedish screening program for prostate cancer later in 2017. Stockholm3 is presently used at some 200 care facilities in Sweden, Norway and Finland.

Links

Prostate cancer